lundi 13 novembre 2017

Onco Actu du 13 novembre 2017

1. Biologie

A Zombie Gene Protects Elephants for Cancer [Wired]

2. Etiologie

What causes breast cancer in women? What we know, don’t know and suspect [The Conversation]

2.10 Etiologie - Alcool

Alcohol and cancer: What does a ‘500% increase’ in risk really mean? [HealthNewsReview]

The New Health Care: A Link Between Alcohol and Cancer? It’s Not Nearly as Scary as It Seems [NY Times]

2.6 Etiologie - Environnement

Glyphosate and the Regulatory Failure of Precaution [The Risk-Monger]

Large U.S. farm study finds no cancer link to Monsanto weedkiller [Reuters]

3.1 Prévention - Tabac

Tobacco Product Use Among Adults — United States, 2015 [MMWR-CDC]

Advances in Tobacco Control [Cancer Research Catalyst]

No more Holy Smokes - Vatican bans sale of cigarettes [Reuters]

1 in 5 U.S. adults used tobacco in 2015: government study [Reuters]

4.12 Biopsies liquides

Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer [NCI]

4.13 Dép., diag. & prono. - Peau

Low-cost device to diagnose skin cancer wins international Dyson award [The Guardian]

4.7 Dép., diag. & prono. - Col de l'utérus

The HPV vaccine and cervical screening: how many tests do you need? [Cancer Research UK]

NHS data shows drop in cervical cancer screening attendance [Cancer Research UK]

5.1 Traitements - Pré-clinique

Fat Cells May Inactivate Chemotherapeutic Drug [AACR]

Study Identifies Potential Drug Combination for Ewing Sarcoma [NCI]

5.12 Immunothérapies

Learning From the Immune System of Long-term Pancreatic Cancer Survivors [Cancer Research Catalyst]

5.12.2 Immunothérapies - CAR-T

When Small Trials Convince [In the Pipeline]

Revolutionary new cancer therapies come with big risks. Drug makers must be prepared [STAT]

Assessment, Grading and Management of Acute Toxicities From CAR-T-Cell Therapy [ESMO]

5.12.3 Immunothérapies-combinaisons

An explosion of PD-1/L1 checkpoint studies is crowding the industry pipeline — and that’s a problem [EndPoints]

5.12.9 Immunothérapies - SITC

Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors [Halozyme]

Juno Dissects ROCKET Deaths, Will Aim Better CAR-T at Leukemia [Xconomy]

Bristol-Myers posts early checkpoint combination data on fast-advancing rival to Incyte’s IDO1 inhibitor [FierceBiotech]

Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors [BMS]

Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003 [BMS]

SITC Scientific Highlights - Nov. 11 [The Sentinel]

SITC Scientific Highlights - Nov. 10 [The Sentinel]

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte [EndPoints]

5.2.3 Pharma - économie

AstraZeneca's Dividend Commitment Comes at a Cost [Bloomberg]

5.3 Traitements - FDA, EMA, NICE...

Advances in Sequencing Likely to Shift Paradigm in Cancer Drug Approvals, FDA Experts Say [RAPS]

Nearly Half of Recent EU Approvals Based on a Single Pivotal Study [RAPS]

5.3.4 Traitements - AMM (FDA, EMA)

U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase [BMS]

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF) [Seattle Genetics]

Adcetris [EMA]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2017 [EMA]

FDA Approves Brentuximab Vedotin for the Treatment of Adult Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides [ESMO]

Inching closer to blockbuster status, Seattle Genetics gets fourth FDA win for Adcetris [EndPoints]

5.4 Traitements - Economie

NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions [FiercePharma]

Merck KGaA's Mavenclad, Roche's Perjeta win 'innovative' coverage deals with NHS [FiercePharma]

NHS England, Roche come to agreement on Perjeta [PharmaTimes]

6. Lutte contre les cancers

ESMO Precision Medicine Glossary Published Today [ESMO]

6.1 Observation

Risk of certain breast cancers coming back remains for at least 20 years after treatment [Cancer Research UK]

Breast cancer 'can return 15 years after treatment ends' [BBC News]

6.10 Politiques

Thousands of drugs face Brexit risk, makers to duplicate testing [Reuters]

6.6 Publications

Carlo Croce, facing misconduct allegations, accuses former colleague of misconduct [Retraction Watch]

6.8 Communication

Behind Belle Gibson's cancer con: 'Everything about this story is extreme' [The Guardian]